Tag: license agreement
Lisata Therapeutics and Catalent Sign SMARTag® Licence Agreement
Lisata Therapeutics and Catalent have signed a global product license agreement that allows Catalent to evaluate Lisata’s certepetide and its analogs into multiple antibody-drug...
Seattle Genetics and Immunomedics Terminate License Agreement for Sacituzumab Govitecan
Seattle Genetics and Immunomedics today confirmed that they have terminated their Exclusive Global Licensing Agreement for sacituzumab govitecan (IMMU-132), Immunomedics breakthrough therapy candidate to...
Pfizer Exercises Options As Part of License Agreement with Philogen
Swiss-Italian Philogen, a clinical-stage biotechnology company engaged in the discovery and development of novel biopharmaceutical products, has confirmed that Pfizer has exercised options granted...
The Business of Bispecific Antibodies: Generating Focused Development Libraries
Bispecific antibodies (BsAb), widely used in the development of anticancer immunotherapy, are proteins capable of simultaneously binding two different epitops, on the same or...
Millennium/Takeda Exercises Commercial License Right for Fleximer Technology
Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited has exercised an option to license commercial rights for its first novel Fleximer® antibody-drug conjugate or ADC developed as part of their collaboration with Mersana Therapeutics, announced earlier this year.
